Navigating Neuropathic Pain:
Bridging the Past and Future of Treatment Strategies

INGENŪ CRO

Introduction

Neuropathic pain, a condition characterized by pain arising as a direct consequence of a lesion or disease affecting the somatosensory system, represents a significant clinical challenge and area of ongoing research.

Neuropathic pain stands as a significant medical challenge, affecting millions worldwide. It is a complex condition resulting from damage or disease that affects the somatosensory nervous system, leading to chronic pain that is often resistant to conventional pain treatments. This pain is not only a physical burden for those affected but also impacts psychological well-being and quality of life. The journey to understand and treat neuropathic pain spans centuries, from early descriptions of nerve pain to the advanced, nuanced understanding of today's medical science.

Historically, neuropathic pain was poorly understood, with treatments focusing on symptom management without addressing underlying causes. Over time, advances in neuroscience have illuminated the complex mechanisms behind neuropathic pain, including the roles of the peripheral and central nervous systems, leading to more targeted and effective treatments.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Epidemiology of Neuropathic Pain

To fully explore the epidemiology of neuropathic pain in a comprehensive manner, addressing its global prevalence, demographic influences, and the various factors contributing to its incidence would be essential.

Age:
The prevalence of neuropathic pain increases with age, due to age-related conditions such as diabetes, cancer, and other diseases that can cause nerve damage. Older adults are particularly susceptible, emphasizing the need for age-specific healthcare strategies and interventions to manage and treat neuropathic pain effectively in this population.

Racial Group:
Differences in neuropathic pain prevalence among racial and ethnic groups can be attributed to genetic variations, socio-economic factors, and disparities in access to healthcare. These differences highlight the importance of understanding and addressing the specific needs of diverse populations in the diagnosis, treatment, and management of neuropathic pain, ensuring equitable healthcare practices.

Location:
Access to healthcare, diagnostic capabilities, and treatment options can vary widely, impacting the recognition and management of neuropathic pain across different regions. This underscores the need for localized healthcare strategies that consider the unique environmental and systemic factors present in each geographic area.

Genetic Predisposition:
Genetic predisposition plays a crucial role in the development and sensitivity to neuropathic pain, with certain genes and familial patterns increasing susceptibility. This highlights the importance of genetic research for identifying at-risk individuals and tailoring prevention and treatment strategies accordingly.

Underlying Health Conditions:
Underlying health conditions can significantly affect the incidence and severity of neuropathic pain by causing direct damage to the nervous system or altering nerve function. These conditions can lead to chronic neuropathic pain by initiating or exacerbating the pathological processes that damage nerve fibers, resulting in altered pain perception and chronic pain states.

Diagnostic Criteria Evolution for Neuropathic Pain

ICD-11 for Neuropathic Pain

The 8E43.0 classification for neuropathic pain underscores the condition as characterized by sensory disturbances such as electric, burning, or shock-like pain, often resulting from various causes including metabolic, nutritional, infectious, genetic, autoimmune, and vasculitic processes.

Common Subgroups for Neuropathic Pain

Diabetic Peripheral Neuropathy: Results from long-term high blood sugar levels, causing nerve damage primarily in the feet and legs.

1E91.5 Postherpetic Neuralgia: A complication of shingles, where nerve fibers are damaged, leading to chronic pain after the rash resolves.

8B82.0 Trigeminal Neuralgia: A chronic pain condition affecting the trigeminal nerve in the face, characterized by intense, sharp pain.

Impact on Clinical and Research Perspectives

The updates in ICD-11 have significant implications for both clinical practice and research. Clinically, they allow for a more nuanced diagnosis and treatment planning, encouraging healthcare providers to consider the full spectrum of factors contributing to a patient's pain experience. For research, these changes pave the way for more comprehensive studies that can explore the complex mechanisms of neuropathic pain, the efficacy of multidisciplinary treatment approaches, and the development of new therapeutic targets.

The transition to more inclusive and multidimensional diagnostic criteria represents an evolutionary path towards understanding and managing neuropathic pain. It acknowledges the complexity of pain and its profound impact on individuals' lives. This evolution encourages a more patient-centered approach to care, where treatment is tailored to the individual's specific circumstances, including their psychological wellbeing and social context.

FDA-Approved Medications for Neuropathic Pain

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Pregabalin (Lyrica)	2005	Pfizer	Binding to calcium channels on nerve cells, reducing the release of neurotransmitters and thus diminishing pain signals	Treats diabetic neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury. Pregabalin works by modulating calcium channel activity, which can reduce pain signals sent by damaged nerves.
Gabapentin (Neurontin)	1993	Pfizer	Similar to pregabalin; modulates calcium channels	Used for postherpetic neuralgia and off-label for various neuropathic pains. It shares a similar mechanism of action with Pregabalin.
Amitriptyline	1961	N/A	Tricyclic antidepressant; affects serotonin and norepinephrine	Off-label use for neuropathic pain management. Its pain-modulating effects are thought to be due to its influence on serotonin and norepinephrine levels in the brain.
Duloxetine	2004	Eli Lilly and Company	Inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, which helps to alleviate pain and improve mood	Therapeutically, it is effective in treating diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain, and major depressive disorder, offering both analgesic and antidepressant effects.
Lidocaine (Topical)	1999	N/A	Topical anesthetic; numbs the area. It works by blocking sodium channels, which are necessary for the transmission of pain signals	Lidocaine is a topical anesthetic that can be used for neuropathic pain relief. Products like patches are applied to the skin to numb the area, providing temporary relief from pain.

Pivotal Endpoints

The Essence of Pivotal Endpoints

Pivotal endpoints in clinical trials are critical in determining the efficacy and safety of new neuropathic pain treatments. As an Australian CRO with a global perspective, we understand the importance of these endpoints, especially for US-based biotechs and scientists.

Correlation to Patient Outcomes

The goal of these trials is to improve patient outcomes. This requires a focus not only on the physiological aspects of neuropathic pain relief but also on the overall quality of life improvements. Endpoints must therefore be relevant to daily living and long-term health.

Common Pivotal Endpoints in Neuropathic Pain Trials

Pain Intensity Reduction:

Measuring changes in pain levels using scales like the Numeric Rating Scale (NRS) or Visual Analog Scale (VAS).

Patient-Reported Outcomes:

Assessments that capture the patient's perception of treatment's impact on pain and its effects on daily activities.

Quality of Life:

Evaluations using standardized questionnaires to understand the treatment's effect on overall well-being and life satisfaction.

Functional Improvements:

Observations of changes in the patient's ability to perform daily tasks and activities, indicating the treatment's practical benefits.

Failed Clinical Trials to Determine Drug Efficacy to Treat Neuropathic Pain

Drug Candidate	Clinical Trial Identifier	Reason for termination/drug failure
Oxytocin	NCT02100956	Slow recruitment (during the pandemic) and lack of funding
Donepezil	NCT01743976	This study was aimed to investigate donepezil's effectiveness in patients with neuropathic pain who were already taking gabapentin or pregabalin, but the study was terminated due to failure to recruit subjects
Ramelteon	NCT00753623	The study was hypothesized to show that Ramelteon would reduce pain scores and improve functional status in subjects with neuropathic pain but the recruitment for the study did not accrue as expected, leading to its termination

Insights from Failed Neuropathic Pain Trials

From the termination of clinical trials like those mentioned above in treating neuropathic pain, we learn about the importance of rigorous recruitment strategies, the necessity for adaptable business and research strategies, and the critical need for a deep understanding of neuropathic pain's pathophysiology. These failures underscore the challenges in targeting the complex mechanisms underlying neuropathic pain and highlight the need for innovative approaches in both drug development and clinical trial design.

Common Failure Points in Neuropathic Pain Clinical Trials

Inadequate Patient Selection

Trials may fail if they include participants who do not meet the strict criteria for neuropathic pain, leading to a mixed study population where the treatment effect is harder to detect.

Placebo Effects

A significant challenge in pain studies, where patients' belief in receiving treatment can lead to perceived pain relief, complicating the assessment of the actual efficacy of the intervention.

Poorly Defined Endpoints

Choosing endpoints that do not accurately reflect meaningful clinical outcomes can result in failure to demonstrate a treatment's effectiveness.

Small Sample Sizes

Without enough participants, trials lack the statistical power to conclusively show treatment effects, leading to inconclusive results.

Heterogeneity in Pain Etiology

Variability in the underlying causes of neuropathic pain among participants can dilute the observed effects of the treatment, making it difficult to draw firm conclusions about its efficacy.

Expanding on the complexities and challenges of conducting clinical trials for neuropathic pain in a comprehensive manner involves addressing several key aspects beyond the above. A detailed analysis would explore statistical and methodological flaws, the impact of patient heterogeneity on study outcomes, and the nuances of measuring subjective outcomes like pain.

Additionally, it would delve into the regulatory landscape, ethical considerations, and the evolving understanding of neuropathic pain mechanisms. Each of these areas contributes to the broader context in which these trials operate, highlighting the importance of robust trial design, patient selection, and endpoint definition to overcome these challenges and successfully develop new treatments.

Trend in Neuropathic Pain Clinical Trials

The observed trend of decreasing drug efficacy estimates in neuropathic pain trials could be due to several evolving factors in clinical research, including:

- Larger study sizes
- Longer study durations
- More rigorous outcome measures
- Changes in study design and reporting practices

These factors highlight the complexity of neuropathic pain as a condition and suggest that as research methodologies have advanced, capturing the true efficacy of treatments has become more nuanced, possibly leading to more conservative estimates of treatment effects that reflect a shift towards recognizing smaller benefits from treatments when evaluated under more stringent and comprehensive research methodologies.

Implications:

- Adjustments in understanding treatment benefits
- Need for refined clinical trial methodologies
- Importance of adapting research approaches to better capture true treatment effects

The decreasing drug efficacy estimates in neuropathic pain trials highlight evolving research methodologies, underlining the necessity for more precise and comprehensive approaches to trial design and outcome measurement. These changes necessitate a recalibration of expectations regarding treatment benefits, emphasizing the importance of continuous improvement in clinical research practices to accurately assess therapeutic potentials.

INGENŪ CRO

Enhancing Protocol Design: Strategies for FDA Approval

To enhance the protocol and increase the possibility of FDA approval for a neuropathic pain study, it is crucial to integrate the latest scientific insights with regulatory compliance. This involves:

- In-depth Understanding of FDA Guidelines
- Robust Trial Design
- Patient-Centric Endpoints
- Precision Medicine Approach
- Rigorous Safety Monitoring
- Regulatory Engagement
- Transparent Data Reporting
- Compliance with Ethical Standards
- Inter-disciplinary Collaboration
- Post-Market Surveillance Plans

A Collaborative Path to Successful Neuropathic Pain Treatments

We invite US-based biotech firms, doctors, and scientists to collaborate with us in enhancing the design of neuropathic pain clinical trials. Our joint efforts will contribute to advancing care, offering new hope to those affected by this condition. Let us work together to set new standards in research and treatment development.

Notable Key Opinion Leaders in Neuropathic Pain and Identified Target PIs

Name	Qualification	Description	Location	Brief Bio
Dr. Mahima Kapoor	PhD, MBBS, FRACP	Consultant Neurologist	New South Wales, Australia	Dr. Mahima Kapoor is a Consultant Neurologist at Regional Specialists Tamworth and at The Alfred Hospital, specializing in neuromuscular and peripheral nerve disorders. She completed her medical degree and neurology training in Melbourne and was awarded the prestigious ANZAN fellowship to further her training in London.
Prof. John D Pollard	FRACP,FRCP,AO (Officer of the Order of Australia)	Director	Sydney, Australia	John D. Pollard, is a professor of neurology at the University of Sydney. He has made significant contributions to the field, particularly in the pathogenesis of acute and chronic inflammatory neuropathies. His research has been crucial in understanding idiopathic demyelinating neuropathy and the efficacy of plasma exchange therapy.
Dr. Thomas Kraemer	MBBS, FRACP	Neurologist	Victoria, Australia	Dr. Thomas Kraemer is a specialized neurologist in Ballarat Central, Victoria. He focuses on diagnosing and treating diseases and disorders of the nervous system, which includes both the central and peripheral systems. His practice covers a broad range of neurological conditions, providing comprehensive care that may involve various treatment modalities.
Dr. Jason C Ray	MBBS, FRACP	Consultant Neurologist	Melbourne, Australia	Dr. Jason C. Ray's work extends to encompass general neurology, offering comprehensive care and treatment strategies for a variety of neurological conditions. His contributions to the medical field are reflected through his involvement in clinical practice and research activities aimed at advancing the understanding and management of neurological diseases.
Dr. Dennis J Cordato	PhD, MBBS, FRACP	Senior Neurologist	New South Wales, Austrlia	Dr. Dennis J. Cordato is a senior neurologist at Liverpool Hospital with significant expertise in neuropharmacology, stroke, and botulinum toxin therapy. He is also an academic, contributing as a Conjoint Associate Professor at UNSW. His dedication to neurological science is evident in his leadership in stroke research and his active role in numerous clinical trials. Dr. Cordato's work significantly impacts stroke and neurology research and patient care in Southwestern Sydney.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com